Download PDF
Geburtshilfe Frauenheilkd 2009; 69(3): 218-232
DOI: 10.1055/s-0029-1185429
Übersicht

© Georg Thieme Verlag KG Stuttgart · New York

Brustkrebs: Mortalitätsreduktion durch Früherkennung und adjuvante Therapie

Breast Cancer: Reduced Mortality by Early Detection and Adjuvant TherapyM. Kaufmann1 , A. Rody1
  • 1Klinik für Gynäkologie und Geburtshilfe, J. W.Goethe-Universität, Frankfurt/Main
Further Information

Publication History

eingereicht 2.2.2009 revidiert 4.2.2009

akzeptiert 9.2.2009

Publication Date:
25 March 2009 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die auch in Deutschland zu beobachtende Mortalitätsreduktion des Mammakarzinoms ist im Wesentlichen auf die Erfolge der adjuvanten Therapie zurückzuführen, da in dem entsprechenden Beobachtungszeitraum (1990–2004) kein flächendeckendes Mammografie-Früherkennungsprogramm existent war. Somit ist mit der Einführung des Screeningprogramms ein weiterer Fortschritt zu erwarten. Insbesondere die Einführung von Brustzentren mit der Definition entsprechender struktureller und qualitativer Vorgaben sowie die Implementierung und konsequente Anwendung von Leitlinien hat die Therapie auf eine evidenzbasierte Grundlage gestellt. Der Paradigmenwandel in der Systemtherapie des Mammakarzinoms ist gekennzeichnet von den molekularbiologischen Erkenntnissen und der Entwicklung entsprechend zielgerichtet einzusetzender neuer Substanzen. Voraussetzung für den optimalen Einsatz dieser Substanzen ist jedoch die qualitätsgesicherte, pathohistologische Bestimmung des entsprechenden Targets sowie die Identifikation neuer prognostischer und prädiktiver Marker. Dieser Entwicklung müssen auch die Studienkonzepte Rechnung tragen, da die empirische Herangehensweise den modernen Ansprüchen in der Onkologie nicht länger gerecht wird.

Abstract

The reduction of breast cancer mortality, which is also observable in Germany, is mainly attributed to the improvement in adjuvant therapy, since a nationwide breast cancer screening program has not been implemented for this period (1990–2004). However, further improvement will be expected after the introduction of a screening program. Notably, the implementation of breast units associated with predefined structural and qualitative demands, as well as the assembly and use of guidelines has changed treatment on an evidence based approach. The paradigm shift in adjuvant therapy is hallmarked by molecular findings and the development of appropriate targeting drugs. An essential prerequisite for the optimal use of those drugs, however, is a quality managed assessment of the respective target, as well as the identification of new predictive and prognostic markers. New study concepts have to account for this progress, since empirical strategies do not longer meet the modern requirements of oncology.

Schlüsselwörter

Mammakarzinom - adjuvante Therapie - Prävention - Früherkennung

Key words

breast cancer - adjuvant therapy - prevention - early detection

Literatur

  • 1 Krebs in Deutschland 2003–2004, Häufigkeiten und Trends. Robert Koch-Institut, Gesellschaft der epidemiologischen Krebsregister e. V. http://www.rki.de/
    Google Scholar
  • 2 Sørlie T, Perou C M, Tibshirani R. et al . Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.  Proc Natl Acad Sci USA. 2001;  98 10869-10874
    CrossrefPubMedGoogle Scholar
  • 3 Silverberg E, Holleb A I. Cancer statistics 1973.  CA Cancer J Clin. 1973;  23 1-27
    PubMedGoogle Scholar
  • 4 Smigal C, Jemal A, Ward E. et al . Trends in breast cancer by race and ethnicity: update 2006.  CA Cancer J Clin. 2006;  56 168-183
    CrossrefPubMedGoogle Scholar
  • 5 Savarese T M, Strohsnitter W C, Low H P. et al . Correlation of umbilical cord blood hormones and growth factors with stem cell potential: implications for the prenatal origin of breast cancer hypothesis.  Breast Cancer Res. 2007;  9 R29
    CrossrefPubMedGoogle Scholar
  • 6 Leitlinien der Arbeitsgemeinschaft Gynäkologische Onkologie, Kommission Mamma, http://www.ago-online.org/ . 
    Google Scholar
  • 7 Gail M H, Brinton L A, Byar D P. et al . Projecting individualized probabilities of developing breast cancer for white females who are being examined annually.  J Natl Cancer Inst. 1989;  81 1879-1886
    CrossrefPubMedGoogle Scholar
  • 8 Fisher B, Costantino J P, Wickerham D L. et al . Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P‐1 Study.  J Natl Cancer Inst. 1998;  90 1371-1388
    CrossrefPubMedGoogle Scholar
  • 9 Vogel V G, Costantino J P, Wickerham D L. et al. . Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P‐2 trial.  JAMA. 2006;  295 2727-2741
    CrossrefPubMedGoogle Scholar
  • 10 Hartmann L C, Schaid D J, Woods J E. et al . Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer.  N Engl J Med. 1999;  340 77-84
    CrossrefPubMedGoogle Scholar
  • 11 Hartmann L C, Sellers T A, Schaid D J. et al . Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers.  J Natl Cancer Inst. 2001;  93 1633-1637
    CrossrefPubMedGoogle Scholar
  • 12 Kauff N D, Satagopan J M, Robson M E. et al . Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.  N Engl J Med. 2002;  346 1609-1615
    CrossrefPubMedGoogle Scholar
  • 13 Rebbeck T R, Lynch H T, Neuhausen S L. et al. . Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.  N Engl J Med. 2002;  346 1616-1622
    CrossrefPubMedGoogle Scholar
  • 14 Finch A, Beiner M, Lubinski J. et al. . Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.  JAMA. 2006;  296 185-192
    CrossrefPubMedGoogle Scholar
  • 15 Eisen A, Lubinski J, Klijn J. et al . Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.  J Clin Oncol. 2005;  23 7491-7496
    CrossrefPubMedGoogle Scholar
  • 16 Rebbeck T R, Friebel T, Wagner T. et al. . Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.  J Clin Oncol. 2005;  23 7804-7810
    CrossrefPubMedGoogle Scholar
  • 17 Early Breast Cancer Trialists' Collaborative Group (EBCTCG) . Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.  Lancet. 2005;  365 1687-1717
    CrossrefPubMedGoogle Scholar
  • 18 Powles T, Eeles R, Ashley S. et al . Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial.  Lancet. 1998;  352 98-101
    PubMedGoogle Scholar
  • 19 Veronesi U, Maisonneuve P, Sacchini V. et al. . Tamoxifen for breast cancer among hysterectomised women.  Lancet. 2002;  359 1122-1124
    CrossrefPubMedGoogle Scholar
  • 20 Cuzick J, Forbes J, Edwards R. et al. . First results from the International Breast Cancer Intervention Study (IBIS‐I): a randomised prevention trial.  Lancet. 2002;  360 817-824
    CrossrefPubMedGoogle Scholar
  • 21 Cuzick J, Powles T, Veronesi U. et al . Overview of the main outcomes in breast-cancer prevention trials.  Lancet. 2003;  361 296-300
    CrossrefPubMedGoogle Scholar
  • 22 Cummings S R, Eckert S, Krueger K A. et al . The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.  JAMA. 1999;  281 2189-2197
    CrossrefPubMedGoogle Scholar
  • 23 Martino S, Cauley J A, Barrett-Connor E. et al. . Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.  J Natl Cancer Inst. 2004;  96 1751-1761
    CrossrefPubMedGoogle Scholar
  • 24 Martino S, Cauley J A, Barrett-Connor E. et al. . Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.  J Natl Cancer Inst. 2004;  96 1751-1761
    CrossrefPubMedGoogle Scholar
  • 25 Harlan L C, Clegg L X, Abrams J. et al . Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987–2000.  J Clin Oncol. 2006;  24 872-877
    CrossrefPubMedGoogle Scholar
  • 26 Olivotto I A, Mates D, Kan L. et al . Prognosis, treatment, and recurrence of breast cancer for women attending or not attending the Screening Mammography Program of British Columbia.  Breast Cancer Res Treat. 1999;  54 73-81
    CrossrefPubMedGoogle Scholar
  • 27 Walter L C, Covinsky K E. Cancer screening in elderly patients: a framework for individualized decision making.  JAMA. 2001;  285 2750-2756
    CrossrefPubMedGoogle Scholar
  • 28 Berry D A, Cronin K A, Plevritis S K. et al. . Effect of screening and adjuvant therapy on mortality from breast cancer.  N Engl J Med. 2005;  353 1784-1792
    CrossrefPubMedGoogle Scholar
  • 29 Erickson V S, Pearson M L, Ganz P A. et al . Arm edema in breast cancer patients.  J Natl Cancer Inst. 2001;  93 96-111
    CrossrefPubMedGoogle Scholar
  • 30 Werner R S, McCormick B, Petrek J. et al . Arm edema in conservatively managed breast cancer: obesity is a major predictive factor.  Radiology. 1991;  180 177-184
    PubMedGoogle Scholar
  • 31 Berg J W. The significance of axillary node levels in the study of breast carcinoma.  Cancer. 1955;  8 776-778
    CrossrefPubMedGoogle Scholar
  • 32 Krag D, Weaver D, Ashikaga T. et al . The sentinel node in breast cancer – a multicenter validation study.  N Engl J Med. 1998;  339 941-946
    CrossrefPubMedGoogle Scholar
  • 33 De Cicco C, Cremonesi M, Luini A. et al . Lymphoscintigraphy and radioguided biopsy of the sentinel axillary node in breast cancer.  Eur J Nucl Med. 1998;  39 2080-2084
    PubMedGoogle Scholar
  • 34 Borgstein P J, Pijpers R, Comans E F. et al . Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection.  J Am Coll Surg. 1998;  186 275-283
    CrossrefPubMedGoogle Scholar
  • 35 Giuliano A E, Barth A M, Spivack B. et al . Incidence and predictors of axillary metastasis in T1 carcinoma of the breast.  J Am Coll Surg. 1996;  183 185-189
    PubMedGoogle Scholar
  • 36 Cox C E, Pendas S, Cox J M. et al . Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer.  Ann Surg. 1998;  227 645-651
    CrossrefPubMedGoogle Scholar
  • 37 Veronesi U, Paganelli G, Viale G. et al . Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series.  J Natl Cancer Inst. 1999;  91 368-373
    CrossrefPubMedGoogle Scholar
  • 38 Guenther J M, Krishnamoorthy M, Tan L R. Sentinel lymphadenectomy for breast cancer in a community managed care setting.  Cancer J Sci Am. 1997;  3 336-340
    PubMedGoogle Scholar
  • 39 Giuliano A E, Kirgan D M, Guenther J M. et al . Lymphatic mapping and sentinel lymphadenectomy for breast cancer.  Ann Surg. 1994;  220 391-398
    PubMedGoogle Scholar
  • 40 McMasters K M, Giuliano A E, Ross M I. et al . Sentinel-lymph-node biopsy for breast cancer – not yet the standard of care.  N Engl J Med. 1998;  339 990-995
    CrossrefPubMedGoogle Scholar
  • 41 Knauer M, Konstantiniuk P, Haid A. et al . Multicentric breast cancer: a new indication for sentinel node biopsy – a multi-institutional validation study.  J Clin Oncol. 2006;  24 3374-3380
    CrossrefPubMedGoogle Scholar
  • 42 Wong S L, Chao C, Edwards M J. et al . Accuracy of sentinel lymph node biopsy for patients with T2 and T3 breast cancers.  Am Surg. 2001;  67 522-526
    PubMedGoogle Scholar
  • 43 Houvenaeghel G, Nos C, Mignotte H. et al . Micrometastases in sentinel lymph node in a multicentric study: predictive factors of nonsentinel lymph node involvement – groupe des chirurgiens de la federation des centres de lutte contre le cancer.  J Clin Oncol. 2006;  24 1814-1822
    CrossrefPubMedGoogle Scholar
  • 44 Viale G, Maiorano E, Pruneri G. et al . Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy.  Ann Surg. 2005;  241 319-325
    CrossrefPubMedGoogle Scholar
  • 45 Changsri C, Prakash S, Sandweiss L. et al . Prediction of additional axillary metastasis of breast cancer following sentinel lymph node surgery.  Breast J. 2004;  10 392-397
    CrossrefPubMedGoogle Scholar
  • 46 Early Breast Cancer Trialists' Collaborative Group (EBCTCG) . Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.  Lancet. 2005;  365 1687-1717
    CrossrefPubMedGoogle Scholar
  • 47 Bueno-de-Mesquita J M, van Harten W H, Retel V P. et al . Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).  Lancet Oncol. 2007;  8 1079-1087
    CrossrefPubMedGoogle Scholar
  • 48 Wittner B S, Sgroi D C, Ryan P D. et al . Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort.  Clin Cancer Res. 2008;  14 2988-2993
    CrossrefPubMedGoogle Scholar
  • 49 Wang Y, Klijn J G, Zhang Y. et al . Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.  Lancet. 2005;  365 671-679
    CrossrefPubMedGoogle Scholar
  • 50 Rody A, Karn T, Pobitschka F. et al . Prognostic value of gene signatures and tumorbiological characteristics in breast cancer patients treated with anthracycline-containing chemotherapy.  Geburtsh Frauenheilk. 2008;  68 1-7
    Article in Thieme ConnectPubMedGoogle Scholar
  • 51 Rody A, Karn T, Holtrich U. et al . “Stem cell like” breast cancers – A model for the identification of new prognostic/predictive markers in endocrine responsive breast cancer exemplified by Plexin B1.  Eur J Obstet Gynecol Reprod Biol. 2008;  139 11-15
    CrossrefPubMedGoogle Scholar
  • 52 Rody A, Holtrich U, Gaetje R. et al . Poor outcome in estrogen receptor positive breast cancers predicted by loss of Plexin B1 the receptor for growth repelling semaphorin 4D.  Clin Cancer Res. 2007;  13 1115-1122
    CrossrefPubMedGoogle Scholar
  • 53 Rody A, Karn T, Ruckhäberle E. et al . Loss of Plexin B1 is highly prognostic in low proliferating ER positive breast cancers – results of a large scale microarray analysis.  Eur J Cancer. 2008;  45 405-413
    PubMedGoogle Scholar
  • 54 Rody A, Karn T, Ruckhäberle E. et al . Differentially expressed genes of reprogrammed human pluripotent stem cells in breast cancer.  Eur J Cancer. 2008;  44 1789-1792
    CrossrefPubMedGoogle Scholar
  • 55 Rody A, Holtrich U, Muller V. et al . c-kit: identification of co-regulated genes by gene expression profiling and clinical relevance of two breast cancer subtypes with stem cell like features. 2006 ASCO Annual Meeting Proceedings Part I.  J Clin Oncol. 2006;  24 622
    PubMedGoogle Scholar
  • 56 Duric V, Stockler M. Patients' preferences for adjuvant chemotherapy in early breast cancer: a review of what makes it worthwhile.  Lancet Oncol. 2001;  2 691-697
    CrossrefPubMedGoogle Scholar
  • 57 http://www.breastinternationalgroup.org/TRANSBIG/MINDACT
  • 58 http://www.cancer.gov/clinicaltrials/digestpage/TAILORx
  • 59 http://www.germanbreastgroup.de/nnbc3/
  • 60 Hoering A, Leblanc M, Crowley J J. Randomized phase III clinical trial designs for targeted agents.  Clin Cancer Res. 2008;  14 4358-4367
    CrossrefPubMedGoogle Scholar
  • 61 Freidlin B, Simon R. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients.  Clin Cancer Res. 2005;  11 7872-7878
    CrossrefPubMedGoogle Scholar
  • 62 Pusztai L, Anderson K, Hess K R. Pharmacogenomic predictor discovery in phase II clinical trials for breast cancer.  Clin Cancer Res. 2007;  13 6080-6086
    CrossrefPubMedGoogle Scholar
  • 63 Goldhirsch A, Wood W C, Gelber R D. et al . 10th St. Gallen conference. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.  Ann Oncol. 2007;  18 1133-1144
    CrossrefPubMedGoogle Scholar
  • 64 Jones S E, Savin M A, Holmes F A. et al . Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.  J Clin Oncol. 2006;  24 5381-5387
    CrossrefPubMedGoogle Scholar
  • 65 Martin M, Pienkowski T, Mackey J. et al. . Adjuvant docetaxel for node-positive breast cancer.  N Engl J Med. 2005;  352 2302-2313
    CrossrefPubMedGoogle Scholar
  • 66 Roché H, Fumoleau P, Spielmann M. et al . Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.  J Clin Oncol. 2006;  24 5664-5671
    CrossrefPubMedGoogle Scholar
  • 67 De Laurentiis M, Cancello G, D'Agostino D. et al . Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials.  J Clin Oncol. 2008;  26 44-53
    CrossrefPubMedGoogle Scholar
  • 68 Mauri D, Pavlidis N, Ioannidis J P. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.  J Natl Cancer Inst. 2005;  97 188-194
    CrossrefPubMedGoogle Scholar
  • 69 Fisher B, Bryant J, Wolmark N. et al . Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.  J Clin Oncol. 1998;  16 2672-2685
    CrossrefPubMedGoogle Scholar
  • 70 Gianni L, Baselga J, Eiermann W. et al .First report of the European Cooperative Trial in operable breast cancer (ECTO): effects of primary systemic therapy (PST) on local-regional disease. Proc ASCO 2002 #132
    Google Scholar
  • 71 von Minckwitz G, Kümmel S, Vogel P. et al. . Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study.  J Natl Cancer Inst. 2008;  100 552-562
    CrossrefPubMedGoogle Scholar
  • 72 von Minckwitz G, Rezai M, Loibl S. et al .Evaluating the efficacy of capecitabine given concomitantly or in sequence to epirubicin/cyclophosphamide → docetaxel as neoadjuvant treatment for primary breast cancer. First efficacy analysis of the GBG/AGO intergroup-study “GeparQuattro”. SABCS 2007 abstr. 79
    Google Scholar
  • 73 von Minckwitz G, Raab G, Caputo A. et al . Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group.  J Clin Oncol. 2005;  23 2676-2685
    PubMedGoogle Scholar
  • 74 Untch M, Konecny G, Ditsch N. et al .Dose-dense sequential epirubicin-paclitaxel as preoperative treatment of breast cancer: results of a randomised AGO study. Proc ASCO 2002 #133
    Google Scholar
  • 75 Untch M, Rezai M, Loibl S. et al .Neoadjuvant treatment of HER2 over-expressing primary breast cancer with trastuzumab given concomitantly to epirubicin/cyclophosphamide → docetaxel ± capecitabine. First analysis of efficacy and safety of the GBG/AGO multicenter intergroup-study “GeparQuattro”. EBCC 2008 LBA
    Google Scholar
  • 76 Smith I, Dowsett M. Comparison of anastrozole vs. tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women: the IMPACT trial. SABCS 2003 #1
    Google Scholar
  • 77 Eiermann W, Paepke S, Appfelstaedt J. et al . Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study.  Ann Oncol. 2001;  12 1527-1532
    CrossrefPubMedGoogle Scholar
  • 78 Semiglazov V F, Semiglazov V V, Dashyan G A. et al . Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.  Cancer. 2007;  110 244-254
    CrossrefPubMedGoogle Scholar
  • 79 Bear H D, Anderson S, Smith R E. et al .A randomized trial comparing preoperative doxorubicin/cyclophosphamide (AC) to preoperative AC followed by preoperative docetaxel (T) and to preoperative AC followed by postoperative T in patients with operable carcinoma of the breast: results of NSABP. SABCS 2004 #26
    Google Scholar
  • 80 Hennessy B T, Hortobagyi G N, Rouzier R. et al . Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy.  J Clin Oncol. 2005;  23 9304-9311
    CrossrefPubMedGoogle Scholar
  • 81 von Minckwitz G, Kaufmann M, Kümmel S. et al .Integrated meta-analysis on 6402 patients with early breast cancer receiving neoadjuvant anthracycline-taxane ± trastuzumab containing chemotherapy. SABCS 2008 #79
    Google Scholar
  • 82 Chen A M, Meric-Bernstam F, Hunt K K. et al . Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience.  J Clin Oncol. 2004;  22 2303-2312
    CrossrefPubMedGoogle Scholar
  • 83 Chen A M, Meric-Bernstam F, Hunt K K. et al . Breast conservation after neoadjuvant chemotherapy.  Cancer. 2005;  103 689-695
    CrossrefPubMedGoogle Scholar
  • 84 Thewes B, Meiser B, Duric V M. et al . What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile?.  Lancet Oncol. 2005;  6 581-588
    CrossrefPubMedGoogle Scholar
  • 85 Anderson W F, Chatterjee N, Ershler W B. et al . Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database.  Breast Cancer Res Treat. 2002;  76 27-36
    CrossrefPubMedGoogle Scholar
  • 86 International Breast Cancer Study Group . Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.  J Natl Cancer Inst. 2002;  94 1054-1065
    PubMedGoogle Scholar
  • 87 AGO (Kommission Mamma) .Diagnostic and treatment of patients with primary and metastatic breast cancer. Guidelines of AGO Breast Commission 2008. http://www.ago-online.org
    Google Scholar
  • 88 Smith I E, Dowsett M, Yap Y S. et al . Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines.  J Clin Oncol. 2006;  24 2444-2447
    CrossrefPubMedGoogle Scholar
  • 89 Early Breast Cancer Trialists' Collaborative Group (EBCTCG) . Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.  Lancet. 2005;  365 1687-1717
    CrossrefPubMedGoogle Scholar
  • 90 Colleoni M, Rotmensz N, Peruzzotti G. et al . Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease.  Ann Oncol. 2006;  17 1497-1503
    CrossrefPubMedGoogle Scholar
  • 91 Adjuvant Breast Cancer Trials Collaborative Group . Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial.  J Natl Cancer Inst. 2007;  99 516-525
    PubMedGoogle Scholar
  • 92 Davidson N E, O'Neill A M, Vukov A M. et al . Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).  J Clin Oncol. 2005;  23 5973-5982
    CrossrefPubMedGoogle Scholar
  • 93 Cuzick J, Ambroisine L, Davidson N. et al. . Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.  Lancet. 2007;  369 1711-1723
    CrossrefPubMedGoogle Scholar
  • 94 Mourits M J, de Vries E G, Willemse P H. et al . Ovarian cysts in women receiving tamoxifen for breast cancer.  Br J Cancer. 1999;  79 1761-1764
    CrossrefPubMedGoogle Scholar
  • 95 Ingle J N. Adjuvant endocrine therapy for postmenopausal women with early breast cancer.  Clin Cancer Res. 2006;  12 (3 Pt 2) 1031s-1036s
    CrossrefPubMedGoogle Scholar
  • 96 Forbes J F, Cuzick J, Buzdar A. et al. . Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.  Lancet Oncol. 2008;  9 45-53
    CrossrefPubMedGoogle Scholar
  • 97 Thürlimann B, Keshaviah A, Coates A S. et al. . A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.  N Engl J Med. 2005;  353 2747-2757
    CrossrefPubMedGoogle Scholar
  • 98 Mouridsen H T, Giobbie-Hurder A, Mauriac L. et al. .BIG 1-98: A randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. SABCS 2008 #13
    Google Scholar
  • 99 Jones S E, Seynaeve C, Hasenburg A. et al .Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer. SABCS 2008 #15
    Google Scholar
  • 100 Kaufmann M, Jonat W, Hilfrich J. et al . Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study.  J Clin Oncol. 2007;  25 2664-2670
    CrossrefPubMedGoogle Scholar
  • 101 Coombes R C, Kilburn L S, Snowdon C F. et al. . Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.  Lancet. 2007;  369 559-570
    CrossrefPubMedGoogle Scholar
  • 102 Ingle J N, Dowsett M, Cuzick J. et al .Aromatase inhibitors versus tamoxifen as adjuvant therapy for postmenopausal women with estrogen receptor positive breast cancer: meta-analyses of randomized trials of monotherapy and switching strategies. SABCS 2008 #12
    Google Scholar
  • 103 Jakesz R, Gnant M, Griel R. et al .Tamoxifen and anastrozole as a sequencing strategy in postmenopausal women with hormone-responsive early breast cancer: updated data from the Austrian breast and colorectal cancer study group trial 8. SABCS 2008 #14
    Google Scholar
  • 104 Joensuu H, Kellokumpu-Lehtinen P L, Bono P. et al . Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.  N Engl J Med. 2006;  354 809-820
    CrossrefPubMedGoogle Scholar
  • 105 Kaufman B, Mackey J, Clemens M. Trastuzumab plus anastrozole prolongs progression-free survival in postmenopausal women with HER2-positive, hormone-dependent metastatic breast cancer (MBC).  Ann Oncol. 2006;  17 (Suppl. 9)
    PubMedGoogle Scholar
  • 106 Smith I, Procter M, Gelber R D. et al. . 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.  Lancet. 2007;  369 29-36
    CrossrefPubMedGoogle Scholar
  • 107 Romond E H, Perez E A, Bryant J. et al . Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.  N Engl J Med. 2005;  353 1673-1684
    CrossrefPubMedGoogle Scholar
  • 108 Slamon D, Eiermann W, Robert N. et al .BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. SABCS 2006 #52
    Google Scholar
  • 109 Gnant M, Mlineritsch B, Schippinger W. et al. . Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: First efficacy results from ABCSG‐12.  J Clin Oncol. 2008;  26
    PubMedGoogle Scholar
  • 110 Eidtmann H, Bundred N J, DeBoer R. et al .The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST. SABCS 2008 #44
    Google Scholar

Prof. Dr. med. Dr. h. c. Manfred Kaufmann

Klinik für Gynäkologie und Geburtshilfe
J. W.Goethe-Universität

Theodor-Stern-Kai 7

60590 Frankfurt

Email: m.kaufmann@em.uni-frankfurt.de

      >